You searched for rivaroxaban - MPR

Your search for rivaroxaban returned 28 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Da Hee Han, PharmD remove

Your search for rivaroxaban returned 28 results

Sort Results:

Relevant Recent

Food Type, Timing Has No Clinically Relevant Impact on Rivaroxaban

Currently, the prescribing information recommends 20mg once daily with an evening meal for the AF indication, and 15mg twice daily with food for 21 days, followed by 20mg once daily with food for the remainder of treatment for the DVT/PE indications.
American College of Cardiology 2013

Net Clinical Benefit of Rivaroxaban for Thrombosis Prevention in ACS Patients

After reports of having met the primary endpoints in the ATLAS-ACS TIMI-52 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

COMPASS Trial Ending Early After Reaching Superiority Endpoint

Janssen announced that the Phase 3 trial, COMPASS, is stopping earlier than planned based on the recommendation of the study's Independent Data Monitoring Committee (DMC), as the primary major adverse cardiovascular events (MACE) endpoint has reached its pre-specified criteria for superiority.